Loading stock data…
Alpha Teknova (TKNO)
$6.88-0.04 (-0.58%)
Market ClosedLast close Sep 8
Alpha Teknova, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alpha Teknova, Inc. in the Healthcare sector is trading at $6.88 with a market capitalization of $233M. Wall Street consensus targets $8.60 (5 analysts), implying a +25.0% move over the next 12 months. The stock is currently near its 52-week high of $7.84, remaining 63.4% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +25.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $12.19M↑ | $11.08M↑ | $9.98M↓ | $10.45M↑ | $10.29M |
| Gross Profit | $4.88M↑ | $3.78M↑ | $3.24M↑ | $3.21M↓ | $3.98M |
| Operating Income | -$2.89M↑ | -$4.30M↑ | -$4.61M↓ | -$4.02M↓ | -$3.39M |
| Net Income | -$3.17M↑ | -$4.55M↑ | -$4.76M↓ | -$4.29M↓ | -$3.57M |
Peer Comparison
JNJUNHPFE
Fundamentals
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured me...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$233.22M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-26.44%
Volume
Today's trading volume
134,752
Recent News
Alpha Teknova Raises Outlook After Record Q2 Revenue at Sidoti Conference
Alpha Teknova (NASDAQ:TKNO) Chief Financial Officer Matt Lowell said the provider of laboratory and bioprocessing reagents is seeing renewed growth, reporting record second-quarter revenue and raising its full-year outlook as biopharma funding and life-science end markets improve. Speaking at the S
Alpha Teknova (TKNO) is a Great Momentum Stock: Should You Buy?
Does Alpha Teknova (TKNO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Believe Alpha Teknova (TKNO) Could Rally 35.45%: Here's is How to Trade
The mean of analysts' price targets for Alpha Teknova (TKNO) points to a 35.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Alpha Teknova (TKNO) Stock Moves Higher on Booming Clinical Demand
Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI […]
Alpha Teknova Q2 Earnings Call Highlights
Alpha Teknova (NASDAQ:TKNO) reported second-quarter revenue growth of 18% from a year earlier, surpassing $12 million for its highest quarterly revenue in the company’s 30-year history. The company raised its full-year revenue outlook, citing first-half performance and confidence in the second half